
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma Inc. is positioned positively within the market due to its innovative cannabinoid-based formulations targeting critical medical conditions, particularly Alzheimer’s disease. The company’s investigational drug assets, such as IGC-AD1, have shown substantial promise in preclinical studies, indicating potential effectiveness in addressing key Alzheimer's disease hallmarks. With an attractive current valuation reinforced by a revised net present value (NPV) analysis suggesting significant upside, combined with anticipated positive data as a catalyst for growth, IGC Pharma holds a favorable outlook in the biotech sector.
Bears say
IGC Pharma Inc. reported a net loss of $1.6 million, corresponding to an earnings per share (EPS) of $(0.02), which aligns with consensus estimates but raises concerns about recurring financial losses. The company's challenges include significant risks related to its investigational drug assets, particularly pertaining to the safety and efficacy of its products in clinical trials, as well as the ability to secure regulatory approvals. Additionally, persistent balance sheet and liquidity risks, compounded by the competitive landscape and fluctuating investor sentiment toward biotech stocks, contribute to a negative outlook for the company's financial stability and growth potential.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares